vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and North American Construction Group Ltd. (NOA). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $860.2M, roughly 1.1× North American Construction Group Ltd.). North American Construction Group Ltd. runs the higher net margin — 4.7% vs 0.7%, a 4.0% gap on every dollar of revenue. Over the past eight quarters, North American Construction Group Ltd.'s revenue compounded faster (58.0% CAGR vs 53.3%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Shanghai Construction (Group) Corporation (SCG) is a Chinese construction and engineering company, ranked as the 16th largest construction company in the world based on 2011 revenues.

ASTH vs NOA — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.1× larger
ASTH
$950.5M
$860.2M
NOA
Higher net margin
NOA
NOA
4.0% more per $
NOA
4.7%
0.7%
ASTH
Faster 2-yr revenue CAGR
NOA
NOA
Annualised
NOA
58.0%
53.3%
ASTH

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ASTH
ASTH
NOA
NOA
Revenue
$950.5M
$860.2M
Net Profit
$6.6M
$40.5M
Gross Margin
19.7%
Operating Margin
1.9%
15.4%
Net Margin
0.7%
4.7%
Revenue YoY
42.9%
Net Profit YoY
184.4%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
NOA
NOA
Q4 25
$950.5M
Q3 25
$956.0M
$860.2M
Q2 25
$654.8M
$573.3M
Q1 25
$620.4M
$297.0M
Q4 24
$665.2M
Q3 24
$478.7M
$636.4M
Q2 24
$486.3M
$439.5M
Q1 24
$404.4M
$244.3M
Net Profit
ASTH
ASTH
NOA
NOA
Q4 25
$6.6M
Q3 25
$373.0K
$40.5M
Q2 25
$9.4M
$26.0M
Q1 25
$6.7M
$11.5M
Q4 24
$-7.8M
Q3 24
$16.1M
$45.5M
Q2 24
$19.2M
$34.1M
Q1 24
$14.8M
$21.8M
Gross Margin
ASTH
ASTH
NOA
NOA
Q4 25
Q3 25
19.7%
Q2 25
18.1%
Q1 25
18.0%
Q4 24
Q3 24
14.0%
Q2 24
14.3%
Q1 24
16.8%
Operating Margin
ASTH
ASTH
NOA
NOA
Q4 25
1.9%
Q3 25
2.0%
15.4%
Q2 25
3.1%
13.6%
Q1 25
3.3%
13.0%
Q4 24
0.1%
Q3 24
5.9%
7.9%
Q2 24
6.2%
8.2%
Q1 24
7.5%
10.5%
Net Margin
ASTH
ASTH
NOA
NOA
Q4 25
0.7%
Q3 25
0.0%
4.7%
Q2 25
1.4%
4.5%
Q1 25
1.1%
3.9%
Q4 24
-1.2%
Q3 24
3.4%
7.1%
Q2 24
3.9%
7.8%
Q1 24
3.7%
8.9%
EPS (diluted)
ASTH
ASTH
NOA
NOA
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
NOA
NOA
Cash + ST InvestmentsLiquidity on hand
$429.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
Total Assets
$2.2B
$1.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
NOA
NOA
Q4 25
$429.5M
Q3 25
$463.4M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Stockholders' Equity
ASTH
ASTH
NOA
NOA
Q4 25
$779.3M
Q3 25
$775.5M
Q2 25
$765.5M
Q1 25
$745.4M
Q4 24
$712.7M
Q3 24
$704.6M
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
ASTH
ASTH
NOA
NOA
Q4 25
$2.2B
Q3 25
$2.2B
$1.7B
Q2 25
$1.4B
$1.7B
Q1 25
$1.3B
$1.7B
Q4 24
$1.4B
Q3 24
$1.3B
$1.5B
Q2 24
$1.3B
$1.5B
Q1 24
$1.2B
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
NOA
NOA
Operating Cash FlowLast quarter
$-2.9M
$140.7M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
3.47×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
NOA
NOA
Q4 25
$-2.9M
Q3 25
$10.0M
$140.7M
Q2 25
$90.9M
$85.4M
Q1 25
$16.6M
$19.0M
Q4 24
$-10.9M
Q3 24
$34.0M
$109.5M
Q2 24
$23.2M
$72.0M
Q1 24
$6.0M
$31.8M
Free Cash Flow
ASTH
ASTH
NOA
NOA
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
NOA
NOA
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
NOA
NOA
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
NOA
NOA
Q4 25
-0.44×
Q3 25
26.69×
3.47×
Q2 25
9.65×
3.28×
Q1 25
2.48×
1.65×
Q4 24
Q3 24
2.11×
2.41×
Q2 24
1.21×
2.11×
Q1 24
0.40×
1.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

NOA
NOA

Segment breakdown not available.

Related Comparisons